Abatacept

BioDrugs

Volumn 20, Issue 1, 2006, Pages 53-61

  Hervey, Pauline S ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BACKACHE; CLINICAL TRIAL; COUGHING; DIZZINESS; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HUMAN; HYPERTENSION; IN VITRO STUDY; INJECTION SITE REACTION; LIMB PAIN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; IMMUNOCONJUGATES;

EID: 33645540973     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200620010-00004     Document Type: Review

References (37)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46 (2): 328-46
2. Scott D. Guidelines for arthritis: ten years on. Clin Med 2001; 1 (5): 389-91
3. Gordon P, West J, Jones H, et al. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001; 28 (11): 2409-15
4. Blumenauer B, Judd M, Cranney A, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003; (4): CD004525
5. Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343 (22): 1594-602
6. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50 (5): 1400-11
7. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63 (9): 1062-8
8. Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005 Sep; 5 (9): 1245-54
9. Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005 Jun; 11 (3 Suppl.): S55-62
10. Nadler S, Townsend R, Mikesell G, et al. Abatacept (CTLA4Ig; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations [abstract no. THU0103]. Ann Rheum Dis 2004 Jul; 63 Suppl. I: 142-3
11. Davis PM, Nadler SG, Suchard SJ. Abatacept differentially modulates human B cell- and dendritic cell-stimulated T cell effector function [abstract no. THU0060]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 128-9
12. Shimoyama Y, Nagafuchi H, Suzuki N, et al. Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis. J Rheumatol 1999; 26 (10): 2094-101
13. Emery P, Westhovens R, Leon G, et al. Beneficial effects of the selective co-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment [abstract no. SAT0074]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 432-3. Plus poster presented at the Annual European Congress of Rheumatology EULAR 2005; 2005 Jun 8-11; Vienna
14. Weisman M, Durez P, Hallegua D, et al. Abatacept (CTLA4Ig; BMS-188667) inhibits T-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkers [abstract no. THU0087]. Ann Rheum Dis 2004 Jun 10; 63 Suppl. I: 138. Plus poster presented at the Annual European Congress of Rheumatology EULAR 2004; 2004 Jun 9-12; Berlin
15. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized; placebo-controlled trial [published erratum appears in Arthritis Rheum 2005; 52 (10): 3321]. Arthritis Rheum 2005; 52 (8): 2263-71
16. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 Nov 13; 349 (20): 1907-15
17. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353 (11): 1114-23
18. Emery P, Russell A, Tate G, et al. Abatacept induces sustained improvements in health-related quality of life, sleep quality and fatigue over 3 years in rheumatoid arthritis patients with inadequate methotrexate responses [abstract no. FRI0484]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 403. Plus poster presented at the Annual European Congress of Rheumatology EULAR 2005; 2005 Jun 8-11; Vienna
19. Russell A, Kremer J, Irazoque F, et al. Abatacept induces sustained improvements in physical function and reductions in pain over 3 years in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract no. FRI0481]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 402-3. Plus poster presented at the Annual European Congress of Rheumatology EULAR 2005; 2005 Jun 8-11; Vienna
20. Genant H, Peterfy C, Paira S, et al. Abatacept significantly inhibits structural damage progression as assessed by the Genant-modified Sharp scoring system in rheumatoid arthritis patients with inadequate methotrexate responses [abstract no. OP0001]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 56
21. Kremer J, Westhovens R, Moreland L, et al. Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in Inadequate responders to Methotrexate) Trial [abstract no. L2]. Arthritis Rheum 2004 Dec; 50 (12): 4095
22. Westhovens R, Russell A, Garza Elizondo M, et al. Abatacept induces increasing and clinically meaningful benefits according to EULAR criteria in rheumatoid arthritis patients with inadequate responses to methotrexate [abstract no. SAT0196]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 471-2. Plus poster presented at the Annual European Congress of Rheumatology EULAR 2005; 2005 Jun 8-11; Vienna
23. Steinfeld S, Moreland L, Abud C, et al. Rapid and significant improvements in the components of the ACR criteria in abatacept-treated rheumatoid arthritis patients patients in the phase III AIM (Abatacept in Inadequate responders to Methotrexate) trial [abstract no. SAT0151]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 457. Plus poster presented at the Annual European Congress of Rheumatology EULAR 2005; 2005 Jun 8-11; Vienna
24. Bristol-Myers Squibb Company. Orencia® (abatacept) prescribing information [online]. Available from URL: http://www.orencia.com [Accessed 2006 Feb 23]
25. Russell A, Sherrer Y, Westhovens R, et al. Abatacept is effective at reducing pain and fatigue, and improving sleep quality in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy in the ATTAIN trial [abstract no. FRI0466]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 397. Plus poster presented at the Annual European Congress of Rheumatology EULAR 2005; 2005 Jun 8-11; Vienna
26. Hull KM. US FDA briefing document for abatacept. BLA 125118/0. 2 September 2005 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4170B1_02_01-FDA-Abatacept.pdf [Accessed 2005 Oct 31]
27. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38 (6): 727-35
28. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38 (1): 44-8
29. Genovese M, Luggen M, Kremer J, et al. The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response to anti-TNF therapy in the ATTAIN trial [abstract no. 277]. Arthritis Rheum 2005; 52 (9 Suppl.): S137
30. Data on file, Bristol-Myers Squibb Company, 2006 Feb 18
31. Genovese M, Luggen M, Schiff M, et al. Sustained improvements through 18 months with abatacept in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy [abstract no. (491)L16]. 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals: Late Breakers; 2005 Nov 12-17; San Diego (CA)
32. Dougados M, Westhovens R, St Clair EW, et al. Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract no. 359]. Arthritis Rheum 2004 Sep; 50 (9 Suppl.): S185
33. Kremer J, Shergy W, Tindall E, et al. Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract no. 351]. Arthritis Rheum 2004 Sep; 50 (9 Suppl.): S182
34. Weinblatt M, Combe B, White A, et al. Safety of abatacept in patients with active rheumatoid arthritis receiving background nonbiologic and biologic DMARDs: 1-year results of the ASSURE Trial [abstract no. OP0012]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 60
35. Moreland L, Weisman M, Alten R, et al. Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: favorable safety and tolerability profile sustained over 2 years [abstract no. 475]. Arthritis Rheum 2004 Sep; 50 (9 Suppl.): S563
36. Moreland L, Kaine J, Espinoza L, et al. Safety of abatacept in rheumatoid arthritis patients in five double-blind, placebo-controlled trials [abstract no. 886]. Arthritis Rheum 2005 Sep; 52 (9 Suppl.): 350. Plus poster presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals; 2005 Nov 12-17; San Diego (CA)
37. Bristol-Myers Squibb Company. US Food and Drug Administration approves ORENCIA. (abatacept) for the treatment of rheumatoid arthritis [media release]. 23 Dec 2005